📰 Nasdaq Vcel News
Page 2 - Nasdaq Vcel News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Vcel. Real-time updates on events, politics, business and more.
January 31, 2024
Shares of Vericel Co. (NASDAQ:VCEL – Get Free Report) have been given an average rating of “Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock […]
January 28, 2024
Vericel Co. (NASDAQ:VCEL – Get Free Report) saw a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a drop of 58.8% from the December 31st total of 5,850,000 shares. Based on an average daily volume of 482,300 shares, the days-to-cover ratio is […]
January 25, 2024
Vericel (NASDAQ:VCEL – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a research report issued on Thursday, Briefing.com reports. The firm presently has a $51.00 price objective on the biotechnology company’s stock, up from their prior price objective of $39.00. Truist Financial’s target […]
January 25, 2024
Vericel Co. (NASDAQ:VCEL – Get Free Report)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $40.82, but opened at $43.41. Vericel shares last traded at $44.01, with a volume of 143,122 shares. Analyst Upgrades and Downgrades A number of brokerages have recently commented on VCEL. StockNews.com […]
January 22, 2024
Vericel Co. (NASDAQ:VCEL – Get Free Report) shares hit a new 52-week high on Monday . The stock traded as high as $40.54 and last traded at $40.54, with a volume of 41200 shares trading hands. The stock had previously closed at $39.67. Analyst Upgrades and Downgrades Several brokerages recently weighed in on VCEL. SVB […]
January 19, 2024
Vericel Co. (NASDAQ:VCEL – Get Free Report) Director Robert L. Md Zerbe sold 2,200 shares of Vericel stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $38.09, for a total value of $83,798.00. Following the completion of the sale, the director now directly owns 30,895 […]
December 20, 2023
Vericel (NASDAQ:VCEL – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Profitability This table compares Vericel and Kodiak Sciences’ […]
December 15, 2023
Curbstone Financial Management Corp increased its holdings in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 10.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,920 shares of the biotechnology company’s stock after acquiring an additional 1,200 shares during […]
December 11, 2023
Brown Capital Management LLC cut its stake in Vericel Co. (NASDAQ:VCEL – Free Report) by 1.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,920,721 shares of the biotechnology company’s stock after selling 121,392 shares during the quarter. Vericel accounts for […]
November 8, 2023
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year...